Startups
SERB Specialty Pharmaceuticals is a global pharmaceutical group with essential products available in over 80 countries through a direct presence in Europe, US, the Middle East, Australia and our broad worldwide network of distributors.
Our portfolio is focused on two key franchises:
o CRITICAL CARE:
• EMERGENCY CARE: wide range of lifesaving medical countermeasures and intensive care medicines.
• SURGERY: drugs and devices for supportive care as well as diagnostic agents.
o RARE DISEASES:
• NEUROLOGY: treatments for rare and severe epileptic and neuromuscular conditions.
• METABOLIC DISORDERS: medicines for paediatric inborn errors of metabolism.
In 2020, we have strengthened our neurology and rare diseases portfolio with the strategic acquisition of Veriton Pharma (veritonpharma.com) in the UK.
In 2021, we have enlarged our critical care medicines portfolio with the acquisition of BTG Specialty Pharmaceuticals (www.btgsp.com) and established our direct presence in US.
We are committed to bringing further innovative solutions into the market by accelerating our acquisitions and enhancing our R&D pipeline.
#proudtosavelives
Our portfolio is focused on two key franchises:
o CRITICAL CARE:
• EMERGENCY CARE: wide range of lifesaving medical countermeasures and intensive care medicines.
• SURGERY: drugs and devices for supportive care as well as diagnostic agents.
o RARE DISEASES:
• NEUROLOGY: treatments for rare and severe epileptic and neuromuscular conditions.
• METABOLIC DISORDERS: medicines for paediatric inborn errors of metabolism.
In 2020, we have strengthened our neurology and rare diseases portfolio with the strategic acquisition of Veriton Pharma (veritonpharma.com) in the UK.
In 2021, we have enlarged our critical care medicines portfolio with the acquisition of BTG Specialty Pharmaceuticals (www.btgsp.com) and established our direct presence in US.
We are committed to bringing further innovative solutions into the market by accelerating our acquisitions and enhancing our R&D pipeline.
#proudtosavelives
Overview
Location
Belgium, Brussels-Capital, City of Brussels
Employees
201-500
Founded date
2013
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 4
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Mar 2, 2021 | SERB completes acquisition of BTG Specialty Pharmaceuticals to create a global leader in critical care medicines | LONDON, March 2, 2021 /PRNewswire/ -- SERB Specialty Pharmaceuticals ("SERB"), a leading European specialty pharmaceutical group focused on prescription medicines that address rare and life-threatening diseases, today announced th... |
| Mar 2, 2021 | SERB completes acquisition of BTG Specialty Pharmaceuticals to create a global leader in critical care medicines | |
| Jun 12, 2017 | Term Sheet — Monday, June 12 | SUNNY SUNDAY Good morning! I hope you were all enjoying a lovely Sunday while Uber’s board held a seven-hour meeting to go over the results of Eric Holder’s independent investigation on Uber’s work environment, and reporters on the beat rac... |
Reviews 0
FAQ about SERB Specialty Pharmaceuticals
When was SERB Specialty Pharmaceuticals founded?
SERB Specialty Pharmaceuticals was founded in 2013.
What has the press written about SERB Specialty Pharmaceuticals?
Parsers VC has collected 4 articles mentioning SERB Specialty Pharmaceuticals, among them “SERB completes acquisition of BTG Specialty Pharmaceuticals to create a global leader in critical care medicines” (Mar 2, 2021) and “SERB completes acquisition of BTG Specialty Pharmaceuticals to create a global leader in critical care medicines” (Mar 2, 2021).
Is SERB Specialty Pharmaceuticals still active?
Yes, SERB Specialty Pharmaceuticals is active; its latest activity on Parsers VC dates from Jul 1, 2026.